Drug Discovery

Monoclonal antibody
#Bioprocessing #Drug discovery #Monoclonal antibodies #Sustainability

How single-use technologies can improve antibodies production  

DDW Editor Reece Armstrong speaks to David Chau, Global Bioprocess Application Specialist, Purification and Filtration Business, Solventum, formerly 3M Health Care, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes.   RA: What are some of the current limitations for producing… Read More

#Exclusive Content

AI concept
#Amino acids #Artificial intelligence (AI) #Biochemistry #Contract Research Organisations (CROs) #Drug discovery #Webinar

Exclusive event: Using AI to discover drugs and improve existing compounds

Traditional drug discovery is time-consuming and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More

Webinar date:
Supported by FUJIFILM Wako
#News

#Blood brain barrier #Drug discovery #Neuroscience

Nutrient research reveals pathway for treating brain disorders 

Dr Rosemary Cater, a University of Queensland (UQ) researcher, has found molecular doorways that could be used to help deliver drugs into the brain to treat neurological disorders. Dr Carter from UQ’s Institute for Molecular Bioscience led a team which discovered that an essential nutrient called choline is transported into the… Read More

#News

The European Medicines Agency in Amsterdam
#Drug discovery #Europe #France #Lithuania #Market reporting #Netherlands #Switzerland

Europe: Where is the drug discovery innovation?

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. Europe is traditionally a life sciences powerhouse, with a strong tradition in… Read More

#Exclusive Content #Market Reports

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

#Cell and gene therapy #Drug discovery #Partnership

ExoXpert partners with Neucore Bio for advanced exosome loading 

ExoXpert has partnered with Neucore Bio to leverage ExoXpert’s platform for evaluation of advanced exosome loading.  Under the agreement, ExoXpert will test and optimise efficient loading of proprietary payloads into exosomes as part of Neucore’s Fibroblast EV Engineering (FiXE(R)) discovery platform.   “This collaboration is an… Read More

#News

Seed fund
#Clinical trials #Drug discovery #Financing

$75m in funding to develop tenosynovial giant cell tumour mAb 

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).  TGCT is a type… Read More

#News

business deal
#Drug discovery #Funding #Mergers and acquisitions #Obesity #Oncology

Reflections from LSX World Congress 

DDW Editor Reece Armstrong and Multimedia Editor Megan Thomas attended LSX World Congress from 29-30 April in London, UK. Having attended a range of sessions and spoken to industry attendees, they reflect on the biotech arm of the event.   Day One  The morning of LSX… Read More

#Exclusive Content #News

Monoclonal antibody
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: Drug discovery and the impact of mAbs

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as… Read More

#News

Clinical research
#Drug discovery #LifeArc #Rare disease #Research and development

LifeArc’s £40m research centres to boost research into rare diseases

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. The virtual centres will focus on areas where there are significant unmet needs. They aim to tackle barriers that ordinarily prevent… Read More

#News

Amino acids
#Amino acids #Artificial intelligence (AI) #Biochemistry #Contract Research Organisations (CROs) #Drug discovery #Webinar

How can AI-AAM address the challenges of drug discovery?

Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join DDW and FUJIFILM Wako on 24 May 3PM BST to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new… Read More

Webinar date:
Supported by FUJIFILM Wako
#News

#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

The last couple of months has seen a number of changes in senior roles in the drug discovery sector. Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma,… Read More

#Business & Investment #News

#Drug discovery

Webinar – Enhancing collaboration between sponsors and contract partners in drug discovery 23.04.2024

Most contemporary drug discovery companies (sponsors) outsource some (or all) drug development to external contract partners, eg. Contract Research Organisations (CROs) and/or Contract Development and Manufacturing Organisations (CDMOs). Communication between sponsor and contract organisation is largely done via email and poorly structured Excel reports which is a highly… Read More

#Webinars